Header Logo

Connection

SANJAY MATHEW to Depressive Disorder, Major

Back to Details
This is a "connection" page, showing publications SANJAY MATHEW has written about Depressive Disorder, Major.
SANJAY MATHEW
Connection Strength
11.983
Depressive Disorder, Major
  1. Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder: A Randomized, Double-Blind Phase 2 Clinical Trial. J Clin Psychopharmacol. 2025 May-Jun 01; 45(3):267-276.
    View in: PubMed
    Score: 0.625
  2. Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression-Advantage Ketamine? JAMA Psychiatry. 2023 12 01; 80(12):1187-1188.
    View in: PubMed
    Score: 0.569
  3. Pharmacotherapy for Treatment-Resistant Depression: Antidepressants and Atypical Antipsychotics. Psychiatr Clin North Am. 2023 06; 46(2):261-275.
    View in: PubMed
    Score: 0.542
  4. Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape. Am J Psychiatry. 2023 03 01; 180(3):190-199.
    View in: PubMed
    Score: 0.540
  5. Replication of distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2023 01 15; 321:140-146.
    View in: PubMed
    Score: 0.527
  6. Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress. Ann Clin Psychiatry. 2022 02; 34(1):33-43.
    View in: PubMed
    Score: 0.501
  7. Does mismatch negativity have utility for NMDA receptor drug development in depression? Braz J Psychiatry. 2022 Jan-Feb; 44(1):61-73.
    View in: PubMed
    Score: 0.498
  8. Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. Int J Neuropsychopharmacol. 2021 05 18; 24(5):383-391.
    View in: PubMed
    Score: 0.477
  9. Distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2021 05 01; 286:320-329.
    View in: PubMed
    Score: 0.471
  10. Is Testosterone an Effective Hormonal Therapy for Women With Antidepressant-Resistant Major Depression? Am J Psychiatry. 2020 10 01; 177(10):891-894.
    View in: PubMed
    Score: 0.457
  11. Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. J Affect Disord. 2018 12 01; 241:514-518.
    View in: PubMed
    Score: 0.394
  12. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology. 2017 Dec; 42(13):2567-2574.
    View in: PubMed
    Score: 0.362
  13. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov. 2017 Jul; 16(7):472-486.
    View in: PubMed
    Score: 0.357
  14. Glycine transporter-I inhibitors: a new class of antidepressant? Biol Psychiatry. 2013 Nov 15; 74(10):710-1.
    View in: PubMed
    Score: 0.284
  15. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013 Oct; 170(10):1134-42.
    View in: PubMed
    Score: 0.281
  16. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010 Jan 15; 67(2):139-45.
    View in: PubMed
    Score: 0.217
  17. Publication bias and the efficacy of antidepressants. Am J Psychiatry. 2009 Feb; 166(2):140-5.
    View in: PubMed
    Score: 0.204
  18. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry. 2009 May 01; 65(9):792-800.
    View in: PubMed
    Score: 0.201
  19. Neurostimulatory therapeutics in management of treatment-resistant depression with focus on deep brain stimulation. Mt Sinai J Med. 2008 May-Jun; 75(3):263-75.
    View in: PubMed
    Score: 0.193
  20. Treatment-resistant depression: recent developments and future directions. Depress Anxiety. 2008; 25(12):989-92.
    View in: PubMed
    Score: 0.189
  21. Intracranial directed connectivity links subregions of the prefrontal cortex to major depression. Nat Commun. 2025 Jul 09; 16(1):6309.
    View in: PubMed
    Score: 0.159
  22. Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD). J Affect Disord. 2025 Dec 01; 390:119836.
    View in: PubMed
    Score: 0.159
  23. Comparing the effects of ECT and intravenous ketamine in psychiatric patients with major depressive episodes. J Affect Disord. 2025 Nov 15; 389:119727.
    View in: PubMed
    Score: 0.158
  24. Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2025 05 01; 8(5):e2514278.
    View in: PubMed
    Score: 0.157
  25. Lack of relationships between ketamine treatment and peripheral neurotrophic and inflammatory factors in a randomized controlled ketamine trial of major depressive disorder. Brain Behav Immun. 2025 Aug; 128:170-178.
    View in: PubMed
    Score: 0.156
  26. Effects of the KCNQ (Kv7) Channel Opener Ezogabine on Resting-State Functional Connectivity of Striatal Brain Reward Regions, Depression, and Anhedonia in Major Depressive Disorder: Results From a Randomized Controlled Trial. Biol Psychiatry. 2025 Oct 01; 98(7):568-577.
    View in: PubMed
    Score: 0.155
  27. Aperiodic (1/f) Neural Activity Robustly Tracks Symptom Severity Changes in Treatment-Resistant Depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2025 Feb; 10(2):186-194.
    View in: PubMed
    Score: 0.152
  28. Beta activity in human anterior cingulate cortex mediates reward biases. Nat Commun. 2024 Jul 15; 15(1):5528.
    View in: PubMed
    Score: 0.148
  29. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study. Neuropsychopharmacology. 2024 Jan; 49(2):467-475.
    View in: PubMed
    Score: 0.141
  30. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. Reply. N Engl J Med. 2023 09 07; 389(10):961-962.
    View in: PubMed
    Score: 0.140
  31. Differentiating depressed adolescent 24 h cortisol secretion in light of their adult clinical outcome. Neuropsychopharmacology. 2003 Jul; 28(7):1336-43.
    View in: PubMed
    Score: 0.137
  32. Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis. J Clin Psychiatry. 2022 12 12; 84(1).
    View in: PubMed
    Score: 0.133
  33. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. J Clin Psychiatry. 2022 11 14; 84(1).
    View in: PubMed
    Score: 0.132
  34. A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. Int J Neuropsychopharmacol. 2022 10 25; 25(10):827-838.
    View in: PubMed
    Score: 0.132
  35. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset. J Clin Psychiatry. 2021 06 15; 82(4).
    View in: PubMed
    Score: 0.120
  36. Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. Am J Psychiatry. 2021 05 01; 178(5):437-446.
    View in: PubMed
    Score: 0.118
  37. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. J Clin Psychiatry. 2020 05 26; 81(4).
    View in: PubMed
    Score: 0.111
  38. Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. J Clin Psychopharmacol. 2020 May/Jun; 40(3):287-292.
    View in: PubMed
    Score: 0.111
  39. Psychotherapy for Mixed Depression and Mixed Mania. Psychiatr Clin North Am. 2020 03; 43(1):199-211.
    View in: PubMed
    Score: 0.108
  40. Trajectories of self-reported sleep disturbance across inpatient psychiatric treatment predict clinical outcome in comorbid major depressive disorder and generalized anxiety disorder. J Affect Disord. 2019 05 15; 251:248-255.
    View in: PubMed
    Score: 0.103
  41. Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology. 2019 06; 44(7):1233-1238.
    View in: PubMed
    Score: 0.101
  42. Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Transl Psychiatry. 2018 12 14; 8(1):280.
    View in: PubMed
    Score: 0.101
  43. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2018 02 01; 175(2):150-158.
    View in: PubMed
    Score: 0.093
  44. The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder. Neuropsychopharmacology. 2017 Jul; 42(8):1739-1746.
    View in: PubMed
    Score: 0.089
  45. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology. 2017 Mar; 42(4):844-853.
    View in: PubMed
    Score: 0.087
  46. Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies. J Clin Psychopharmacol. 2015 Aug; 35(4):454-9.
    View in: PubMed
    Score: 0.080
  47. Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. Eur Neuropsychopharmacol. 2015 Aug; 25(8):1082-90.
    View in: PubMed
    Score: 0.078
  48. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015 Mar 13; 40(5):1084-90.
    View in: PubMed
    Score: 0.078
  49. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015 Mar; 76(3):247-52.
    View in: PubMed
    Score: 0.078
  50. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015 May; 1345:47-58.
    View in: PubMed
    Score: 0.077
  51. Hippocampal volume and the rapid antidepressant effect of ketamine. J Psychopharmacol. 2015 May; 29(5):591-5.
    View in: PubMed
    Score: 0.075
  52. In vivo (1)H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder. Neurosci Lett. 2014 May 21; 569:74-9.
    View in: PubMed
    Score: 0.073
  53. A case of sustained remission following an acute course of ketamine in treatment-resistant depression. J Clin Psychiatry. 2011 Mar; 72(3):414-5.
    View in: PubMed
    Score: 0.059
  54. Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder. NMR Biomed. 2010 Jul; 23(6):643-50.
    View in: PubMed
    Score: 0.056
  55. Neurobiological mechanisms in major depressive disorder. CMAJ. 2009 Feb 03; 180(3):305-13.
    View in: PubMed
    Score: 0.051
  56. Effects of KCNQ potassium channel modulation on ventral tegmental area activity and connectivity in individuals with depression and anhedonia. Mol Psychiatry. 2025 Aug; 30(8):3686-3694.
    View in: PubMed
    Score: 0.039
  57. Efficacy of Deep Brain Stimulation for Treatment-Resistant Depression: Systematic Review and Meta-Analysis. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 Dec; 9(12):1239-1248.
    View in: PubMed
    Score: 0.037
  58. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N Engl J Med. 2023 06 22; 388(25):2315-2325.
    View in: PubMed
    Score: 0.034
  59. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. J Affect Disord. 2020 01 01; 260:131-139.
    View in: PubMed
    Score: 0.026
  60. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019 03; 36(3):235-243.
    View in: PubMed
    Score: 0.025
  61. Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Mol Psychiatry. 2019 04; 24(4):576-587.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.